MESO

Mesoblast Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 4/10
  • Momentum↑ 6/10
Mesoblast sales and earnings growth
MESO Growth
Neutral
  • Revenue Y/Y↑ 129.28%
  • EPS Y/Y↑ 19.66%
  • FCF Y/Y↑ 20.30%
Mesoblast gross and profit margin trends
MESO Profitability
Neutral
  • Gross margin ↑ 70.20%
  • EPS margin↓ -593.90%
  • ROIC↓ -103.10%
Mesoblast net debt vs free cash flow
MESO Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -3.4

Mesoblast stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗